Genscript Biotech Co. (OTCMKTS:GNNSF – Get Free Report) traded down 0% on Friday . The company traded as low as C$4.50 and last traded at C$4.50. 460 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 4,750 shares. The stock had previously closed at C$4.50.
Genscript Biotech Price Performance
The company has a 50-day moving average price of C$2.34 and a 200-day moving average price of C$1.84.
About Genscript Biotech
GenScript Biotech Corporation is a global contract research, development and manufacturing organization (CDMO) specializing in synthetic biology and biopharmaceutical services. Founded in 2002, the company provides end-to-end solutions that span gene and peptide synthesis, recombinant protein expression, custom antibody discovery and cell line development. GenScript’s integrated platforms support early-stage discovery through to process development, enabling academic institutions, biotech innovators and pharmaceutical companies to accelerate research timelines.
The company’s core offerings include molecular biology services such as DNA construction, gene editing using CRISPR/Cas9 technology and high-throughput peptide libraries.
Featured Stories
- Five stocks we like better than Genscript Biotech
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Genscript Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genscript Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
